人工多能性幹細胞 (iPSC) ：世界市場

世界の人工多能性幹細胞 (iPSC) の市場規模は、2023年の34億米ドルから、予測期間中は9.1%のCAGRで推移し、2028年末には52億米ドルの規模に成長すると予測されています。

非統合法の部門は、2023年の21億米ドルから、CAGR 10.1%で推移し、2028年には34億米ドルに成長すると予測されています。統合法の部門は、2023年の13億米ドルから、CAGR 7.5%で推移し、2028年には18億米ドルに成長すると予測されています。

当レポートでは、世界の人工多能性幹細胞 (iPSC) の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、臨床試験・特許の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場の展望
• 調査範囲
• 市場概要

第2章 市場概要

• 人工多能性幹細胞 (iPSC) の生成

第3章 市場力学

• 世界市場力学
• 市場促進要因
• 慢性疾患の増加
• バイオテクノロジー産業への投資の増加
• 個別化医療の需要の増加
• 医薬品研究開発への投資の増加
• 効果的な医薬品の発見と開発プロセスへの需要
• 動物実験の最小化
• 市場抑制要因
• 高い開発コストと熟練労働力の不足
• iPSCベースの疾患モデル、細胞治療、創薬に関連する課題
• 市場機会
• 技術の進歩
• iPSCバンキングの成長

第4章 新興技術と開発

• iPSC研究の進歩
• リプログラミング技術
• 遺伝子編集技術
• 3Dオルガノイド
• 再生医療
• iPSC研究におけるAIの進化と現在の応用

第5章 臨床試験の分析

• 臨床試験

第6章 特許分析

• 特許分析

第7章 市場セグメンテーション分析

• セグメンテーションの内訳
• 概要
• iPSCの生成：リプログラミング手法別の市場分析
• iPSC市場：生成法別
• iPSC市場：用途別
• 学術研究
• 薬理毒性スクリーニング
• 医薬品の発見と開発
• 疾患モデリング
• 組織工学
• 細胞療法
• 世界市場
• iPSCの地域市場：用途別
• iPSC由来組織細胞市場：タイプ別
• 心筋細胞
• 神経細胞
• 内皮細胞
• 肝細胞
• その他の細胞
• iPSC由来組織細胞市場：タイプ別
• 世界市場
• iPSC由来組織細胞市場：用途別
• 世界市場
• iPSC市場：製品機能別
• 世界市場
• iPSCの地域市場：製品機能別
• iPSC市場：エンドユーザー別
• iPSC受託サービスのタイプ
• 主要企業
• 世界市場
• 地理的内訳
• iPSC市場：地域別
• 米国
• 欧州
• アジア太平洋
• その他の地域

第8章 競合情報

• 競合情勢：概要
• 戦略分析
• 合意
• コラボレーション・戦略的提携
• パートナーシップ
• 新製品の開発・発売
• 拡張・買収
• 資金調達
• 承認・臨床試験
• その他
• 主要企業：製品タイプ別

第9章 付録

• 調査手法
• 略語
• 出典
• 企業プロファイル
• ATCC
• AXOL BIOSCIENCE LTD.
• BIO-TECHNE
• FUJIFILM CELLULAR DYNAMICS INC.
• LONZA
• MERCK KGAA
• NCARDIA
• QIAGEN
• REPROCELL INC.
• STEMCELL TECHNOLOGIES
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
• Table 1 : Projected Number of Adults 50 Years and Older with >=1 Chronic Condition in the United States, 2020-2050
• Table 2 : The U.S. NIH Funding for Various Disease Conditions, 2019-2025
• Table 3 : Brief Information on iPSC Repositories
• Table 4 : Induced Pluripotent Stem Cells Pipeline, 2023
• Table 5 : List of Selected Patents Published on iPSC Technology, 2021
• Table 6 : List of Selected Patents Published on iPSC Technology, 2022
• Table 7 : List of Selected Patents Published on iPSC Technology, 2023
• Table 8 : List of Selected Patents Published on iPSC Technology, Till August 2024
• Table 9 : Summary of Different Reprogramming Methods
• Table 10 : Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
• Table 11 : Global Market for Induced Pluripotent Stem Cells, by Method, Through 2028
• Table 12 : Selected Interventional Clinical Trials of iPSC-based Cell Therapy
• Table 13 : Global Market for Induced Pluripotent Stem Cells, by Application, Through 2028
• Table 14 : The U.S. Market for Induced Pluripotent Stem Cells, by Application, Through 2028
• Table 15 : European Market for Induced Pluripotent Stem Cells, by Application, Through 2028
• Table 16 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Application, Through 2028
• Table 17 : RoW Market for Induced Pluripotent Stem Cells, by Application, Through 2028
• Table 18 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, Through 2028
• Table 19 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Species, Through 2028
• Table 20 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Application, Through 2028
• Table 21 : Global Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
• Table 22 : The U.S. Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
• Table 23 : European Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
• Table 24 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
• Table 25 : RoW Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
• Table 26 : Global Market for Induced Pluripotent Stem Cells, by End Use, Through 2028
• Table 27 : Major Companies Providing iPSC Contract Services, by State/Country
• Table 28 : Global Market for Induced Pluripotent Stem Cell Contract Services, by Region, Through 2028
• Table 29 : Global Market for Induced Pluripotent Stem Cells, by Region, Through 2028
• Table 30 : The U.S. Market for Induced Pluripotent Stem Cells, by State, Through 2028
• Table 31 : European Market for Induced Pluripotent Stem Cells, by Country, Through 2028
• Table 32 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Country, Through 2028
• Table 33 : Agreements: Induced Pluripotent Stem Cells Market, 2019-2024
• Table 34 : Collaborations and Strategic Alliances: Induced Pluripotent Stem Cells Market, 2019-2024
• Table 35 : Partnerships: Induced Pluripotent Stem Cells Market, 2020-2023
• Table 36 : New Product Development and Launches: Induced Pluripotent Stem Cells Market, 2020-2023
• Table 37 : Expansions and Acquisitions: Induced Pluripotent Stem Cells Market, 2020-2023
• Table 38 : Fund Raising: Induced Pluripotent Stem Cells Market, 2020-2024
• Table 39 : Approvals and Clinical Trials: Induced Pluripotent Stem Cells Market, 2020-2024
• Table 40 : Other Competitive Strategies: Induced Pluripotent Stem Cells Market, 2020-2024
• Table 41 : Major Companies in the Induced Pluripotent Stem Cells Market
• Table 42 : Glossary of Terms Used in This Report
• Table 43 : Report Information Sources
• Table 44 : ATCC: Company Snapshot
• Table 45 : ATCC: Product Portfolio
• Table 46 : ATCC: News/Key Developments, 2023 and 2024
• Table 47 : Axol Bioscience Ltd.: Company Snapshot
• Table 48 : Axol Bioscience Ltd.: Product Portfolio
• Table 49 : Axol Bioscience Ltd.: News/Key Developments, 2021-2024
• Table 50 : Bio-Techne: Company Snapshot
• Table 51 : Bio-Techne: Financial Performance, FY 2022 and 2023
• Table 52 : Bio-Techne: Product Portfolio
• Table 53 : Bio-Techne: News/Key Developments, 2021-2023
• Table 54 : Fujifilm Cellular Dynamics Inc.: Company Snapshot
• Table 55 : Fujifilm Cellular Dynamics Inc.: Product Portfolio
• Table 56 : Fujifilm Cellular Dynamics Inc.: News/Key Developments, 2021-2023
• Table 57 : Lonza: Company Snapshot
• Table 58 : Lonza: Financial Performance, FY 2022 and 2023
• Table 59 : Lonza: Product Portfolio
• Table 60 : Lonza: News/Key Developments, 2020
• Table 61 : Merck KGaA: Company Snapshot
• Table 62 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 63 : Merck KGaA.: Product Portfolio
• Table 64 : Merck KGaA: News/Key Developments, 2021-2024
• Table 65 : Ncardia: Company Snapshot
• Table 66 : Ncardia: Product Portfolio
• Table 67 : Ncardia: News/Key Developments, 2021-2024
• Table 68 : Qiagen: Company Snapshot
• Table 69 : Qiagen: Financial Performance, FY 2022 and 2023
• Table 70 : Qiagen: Product Portfolio
• Table 71 : REPROCELL Inc.: Company Snapshot
• Table 72 : REPROCELL Inc.: Product Portfolio
• Table 73 : REPROCELL Inc.: News/Key Developments, 2021-2024
• Table 74 : STEMCELL Technologies.: Company Snapshot
• Table 75 : STEMCELL Technologies: Product Portfolio
• Table 76 : STEMCELL Technologies: News/Key Developments, 2021-2022
• Table 77 : Takara Bio Inc.: Company Snapshot
• Table 78 : Takara Bio Inc.: Financial Performance, FY 2022 and 2023
• Table 79 : Taraka Bio Inc.: Product Portfolio
• Table 80 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 81 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
• Table 82 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 83 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024

List of Figures

• Summary Figure : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, 2020-2028
• Figure 1 : Methodology for the Generation of Induced Pluripotent Stem Cells
• Figure 2 : Snapshot of the Market Dynamics for iPSCs
• Figure 3 : Venture Averages for Biopharma Therapeutics and Platform Companies, 2010-2024
• Figure 4 : Personalized Medicines Contribution in Total FDA Approvals, 2015-2023
• Figure 5 : Global Pharmaceutical R&D Spending, by Select Country/Region, 2010-2022
• Figure 6 : Phases of the Pharmaceutical Industry Research and Development Process
• Figure 7 : iPSC-derived Organoids Used for Drug Screening
• Figure 8 : Temporal Distribution of Studies Using ESCs, iPSCs, Somatic Cell Nuclear Transfer (SCNT) Cells and Parthenotic PSCs (pPSCs), Jan 1, 2011-Dec 13, 2022
• Figure 9 : Clinical-trial Analysis: Induced Pluripotent Stem Cells, as of August 2024
• Figure 10 : Number of Patents Documented Over Time on iPSC Technology, 2010-2024
• Figure 11 : Number of Granted Patents Documents on iPSC Technology, by Country, 2021-2024
• Figure 12 : PubMed Citations and Human iPSC Lines Registered in hPSCreg and EBiSC, 2007-2022
• Figure 13 : Published Applications of hiPSC Technology from Top 20 Pharma Companies, 2010-2020
• Figure 14 : Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, 2020-2028
• Figure 15 : Global Market Shares of Induced Pluripotent Stem Cells, by Reprogramming Method, 2022
• Figure 16 : Global Market for Induced Pluripotent Stem Cells, by Method, 2020-2028
• Figure 17 : Global Market Shares of Induced Pluripotent Stem Cells, by Method, 2022
• Figure 18 : Utility of hiPSCs to Humanize Drug Discovery
• Figure 19 : Autologous and Allogeneic iPSC-Based Cell Therapy
• Figure 20 : Global Market for Induced Pluripotent Stem Cells, by Application, 2020-2028
• Figure 21 : Global Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
• Figure 22 : The U.S. Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
• Figure 23 : European Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
• Figure 24 : Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
• Figure 25 : RoW Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
• Figure 26 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2020-2028
• Figure 27 : Global Market Shares of Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2022
• Figure 28 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Species, 2020-2028
• Figure 29 : Global Market Shares of Induced Pluripotent Stem Cell-derived Tissue Cells, by Application, 2022
• Figure 30 : Global Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
• Figure 31 : The U.S. Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
• Figure 32 : European Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
• Figure 33 : Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
• Figure 34 : RoW Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
• Figure 35 : Global Market Shares of Induced Pluripotent Stem Cells, by End Use, 2022
• Figure 36 : Global Market Shares of Induced Pluripotent Stem Cell Contract Services, by Region, 2022
• Figure 37 : Global Market Shares of Induced Pluripotent Stem Cells, by Region, 2022
• Figure 38 : NIH Spending on Induced Pluripotent Stem Cell Research in the U.S., 2015-2023
• Figure 39 : The U.S. Market Shares of Induced Pluripotent Stem Cells, by State, 2022
• Figure 40 : European Market Shares of Induced Pluripotent Stem Cells, by Country, 2028
• Figure 41 : Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Country, 2022
• Figure 42 : Global Market Shares of Induced Pluripotent Stem Cells, by Key Strategies Adopted, 2019-2024
• Figure 43 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
• Figure 44 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
• Figure 45 : Lonza: Revenue Share, by Business Unit, FY 2023
• Figure 46 : Lonza: Revenue Share, by Country/Region, FY 2023
• Figure 47 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
• Figure 48 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
• Figure 49 : Qiagen: Revenue Share, by Business Unit, FY 2023
• Figure 50 : Qiagen: Revenue Share, by Country/Region, FY 2023
• Figure 51 : Takara Bio Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 52 : Takara Bio Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 53 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 54 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.

The global market for iPSCs generated by non-integrated method is expected to grow from $2.1 billion in 2023 to reach $3.4 billion by 2028, at a CAGR of 10.1% from 2023 to 2028.

The global market for iPSCs generated by integrated method is expected to grow from $1.3 billion in 2023 to reach $1.8 billion by 2028, at a CAGR of 7.5% from 2023 to 2028.

Report Scope

The scope of this study encompasses an investigation of the market. BCC Research analyzes this market based on application type, product function, generation of iPSC and types of iPSC derived cells and species. Application-based market segments include drug development and toxicity testing, academic research and regenerative medicine. Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis. iPSC-derived cell-type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells and other cell types. Other cell types include astrocytes, fibroblasts and hematopoietic progenitor cells. BCC Research determines the current market status in each segment, examines its impact on future needs and presents growth forecasts through 2028.

The report also provides a detailed analysis of the market's drivers, restraints, challenges and opportunities. In addition, the report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios and recent developments. it also provides detailed information on this market, emerging technologies and new developments, regulatory landscape, patent analysis, pipeline analysis and investment outlook and deals.

Report Includes

• 28 data tables and 56 additional tables
• An analysis of the global market for induced pluripotent stem cells (iPSCs) or artificial stem cells
• Analyses of global market trends, with market revenue data from 2020 to 2023, and projected CAGRs through 2028
• Estimate of the size and revenue prospects of the global market, along with a market share analysis by reprogramming method, generation method, application, product function, iPSC-derived cell type, species, end use, and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
• A Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Insights into iPSC research activity, emerging technologies, clinical trials and pipeline products
• Patent activity and analysis of recent patent grants/publications
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
• Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook
• Profiles of market leaders, including Fujifilm Cellular Dynamics (FCDI) Inc., Axol Bioscience Ltd., Merck KGaA, Thermo Fisher Scientific Inc., and Takara Bio Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Introduction
• Induced Pluripotent Stem Cells (iPSC) Generation

Chapter 3 Market Dynamics

• Global Market Dynamics
• Market Drivers
• Increasing Prevalence of Chronic Diseases
• Increasing Investment in Biotechnology Industry
• Increasing Demand for Personalized Medicines
• Increasing Investments for Drug Research and Development
• Demand for Effective Drug Discovery and Development Process
• Minimizing Animal Testing
• Market Restraints
• High Development Costs and Lack of Skilled Workforce
• Challenges Associated with iPSC-based Disease Modeling, Cell Therapy and Drug Discovery
• Market Opportunities
• Technological Advances
• Growth in iPSC Banking

Chapter 4 Emerging Technologies and Developments

• Advances in the iPSC Research
• Reprogramming Technologies
• Gene Editing Technologies
• 3D Organoids
• Regenerative Medicine
• Evolution and Current Application of Artificial Intelligence (AI) in iPSC Research

Chapter 5 Clinical Trial Analysis

• Clinical Trials

Chapter 6 Patent Analysis

• Patent Analysis

Chapter 7 Market Segmentation Analysis

• Segmentation Breakdown
• Overview
• Generation of Induced Pluripotent Stem Cells -- Market Analysis, by Reprogramming Method
• Market for Induced Pluripotent Stem Cells, by Generation Method
• Market for Induced Pluripotent Stem Cells, by Application
• Academic Research
• Pharmaco-toxicological Screening
• Drug Discovery and Development
• Disease Modeling
• Tissue Engineering
• Cell Therapy
• Global Market
• Regional Markets for iPSCs, by Application
• iPSC-derived Tissue Cell Market, by Type
• Cardiomyocytes
• Neurons
• Endothelial Cells
• Hepatocytes
• Other Cells
• iPSC-derived Tissue Cell Market, by Species
• Global Market
• iPSC-derived Tissue Cell Market, by Application
• Global Market
• Market for Induced Pluripotent Stem Cells, by Product Function
• Global Market
• Regional Markets for iPSCs, by Product Function
• Market for Induced Pluripotent Stem Cells, by End Use
• Induced Pluripotent Stem Cell Contract Service Types
• Major Players
• Global Market
• Geographic Breakdown
• Market for Induced Pluripotent Stem Cells, by Region
• The U.S.
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Competitive Intelligence

• Competitive Landscape -- Overview
• Strategic Analysis
• Agreements
• Collaborations & Strategic Alliances
• Partnerships
• New Product Development and Launches
• Expansions and Acquisitions
• Fund Raising
• Approval and Clinical Trials
• Others
• Major Companies in Induced Pluripotent Stem Cells Market, by Type of Offerings

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ATCC
• AXOL BIOSCIENCE LTD.
• BIO-TECHNE
• FUJIFILM CELLULAR DYNAMICS INC.
• LONZA
• MERCK KGAA
• NCARDIA
• QIAGEN
• REPROCELL INC.
• STEMCELL TECHNOLOGIES
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.